Angel M. Charles was recently awarded both the Howard Hughes Medical Institute Medical Fellowship and a Doris Duke Research Mentorship Award. The long-term aim of her project is to develop a targeted immunotherapy that can treat HPV induced cancers with high specificity and minimal adverse effects. She is working in the laboratory of David Scheinberg at MSKCC that developed a T-cell receptor mimic (TCRm) monoclonal antibody (mAb) which is specific for a Human Papilloma Virus (HPV) peptide (protein fragment) bound to a Human Leukocyte Antigen (HLA) complex, which presents antigens to T cells. The TCRm binds the HPV-peptide/HLA complex and induces killing of virus-infected cells. The short-term aim of her project is to identify and evaluate potential off-target binding of the TCRm to normal peptides in human tissue. On behalf of the Office of Diversity and Inclusion, Congratulations!!